Skip to main
PIP
PIP logo

Altimmune (PIP)

$0.00

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

Buy Altimmune (PIP) Stock

About Altimmune (PIP)

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherape...read more
Market cap
Today's volume
Revenue (TTM)$20K
Avg. daily volume
EBITDA (TTM)-$98.03M
Open
Price / earnings ratio
Today's range
Debt / equity1.12x
52 week range
5 year debt / equity
Beta (LTM)
Interest coverage-11463.56x
Dividend & yield— (—)
Current ratio15.82x
Ex-dividend date
Next earnings
Dividend payable date

Frequently Asked Questions (FAQ)

How to buy Altimmune stock on Public

  1. 1

    Sign up for a brokerage account on Public

    It’s easy to get started. You can sign up for an account directly on our website or by downloading the Public app for iOS or Android.

  2. 2

    Add funds to your Public account

    There are multiple ways to fund your Public account—from linking a bank account to making a deposit with a debit card or wire transfer.

  3. 3

    Choose how much you'd like to invest in Altimmune stock

    Navigate to the Explore page. Then, type Altimmune into the search bar. When you see Altimmune stock appear in the results, tap it to open up the purchase screen.

  4. 4

    Manage your investments in one place

    You can find your newly purchased Altimmune stock in your portfolio—alongside the rest of your stocks, ETFs, crypto, treasuries, and alternative assets.

Buy Altimmune (PIP) Stock

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.